Mr. Glorikian currently serves on the public boards of GeneNews Ltd. (GEN.TO) and Biocartis (BCART.BR) and Transparency Life Sciences (Private). Mr. Glorikian is also a co-founder and an advisory board member to DrawBridge Health.

Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University. Mr. Glorikian has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many others.

The talk will focus on precision medicine that is personalized to the characteristics of each patient and growing use of AI for drug discovery, clinical trial design and to help diagnose condition and recommend treatment options. Advances in genetics, and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality. AI based predictive modeling of biological processes and drugs becomes significantly more sophisticated and widespread. AI will identify patients to enroll in clinical trials based on factors such as genetic information to target specific populations, thereby enabling trials that are smaller, shorter, less expensive, and more powerful. Trials are monitored in real time to rapidly identify safety or operational issues requiring action, resulting in cost savings.